KRAS and neoplasm: In a landmark study by Yao and colleagues, in transgenic mice models of PDAC, oncogenic KRAS induced SDC1 cell surface overexpression, where it regulated macropinocytosis, a crucial metabolic pathway that fuels PDAC cell growth and promotes tumor progression.18